Smooth Drug Development August 2026 News Release
News – August 2026
Throughout August, our clinical
programs continued to make steady progress, supported by key regulatory
submissions, active feasibility studies, and strategic partnerships across
global regions.
Clinical and Scientific Departments News:
Phase I-IV Clinical Trials
·
A Phase III Dermatology Study: 13 site-screening
visits were conducted in the EAEU region.
·
A Phase I Hodgkin lymphoma Study: 6 subjects
were screened, and 4 were randomized in the EAEU region.
·
A Phase I Locally advanced or metastatic
non-small cell lung cancer (NSCLC) Study: 13 subjects were screened, and 1 was
randomized.
·
A Phase III Immunology Study: All 18 patients
have been enrolled in the study in Uzbekistan.
·
A Phase IV Vitamin Support Regimens Study: The
Statistical Report for the vitamin support regimens clinical study has been
prepared and submitted to the sponsor for review.
·
A Phase III Infectious Disease Study: The first
10 patients were screened in Uzbekistan, and regulatory authority approval was
received in Pakistan.
·
A Phase III Gynecology Study I: 247 patients
were screened; 200 patients were randomized.
·
A Phase III Gynecology study II: A total of 56
patients were screened, and 42 patients were randomized.
Bioequivalence
(BE) Study
·
A BE study in healthy volunteers: The clinical
trial authorization has been obtained in EAEU region. We are currently awaiting
confirmation from the Sponsor regarding the expected timeline for delivery of
the study drug.
Business Development News:
Our Business Development team has
been actively expanding partnerships and exploring new opportunities through
strategic discussions and conference participation. Key Partner Engagements
·
The Smooth Drug Development Pakistan team
attended the 2nd Clinical Trials Summit of Pakistan in Islamabad, Pakistan.Follow-up communications are ongoing
with multiple companies, with several discussions advancing toward potential
partnerships and future clinical development projects.